Latest Breaking News On - Valerie malyvanh jansen - Page 1 : comparemela.com

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesKohei shitaraValerie malyvanh jansenNational cancer center hospitalDepartment of gastrointestinal oncologyPrnewswire elevation oncology incCorporate communications investor relationsElevation oncology incExchange commissionChief medical officerGastrointestinal oncologyNational cancer center hospital eastElevation oncologyPrivate securities litigation reform actOncology investorCorporate communications

Elevation Oncology (ELEV) Expands Ongoing Phase 1 Clinical Trial of EO-3021

Elevation Oncology (ELEV) Expands Ongoing Phase 1 Clinical Trial of EO-3021
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesValerie malyvanh jansenKohei shitaraElevation oncology incDepartment of gastrointestinal oncologyNational cancer center hospitalElevation oncologyMalyvanh jansenChief medical officerGastrointestinal oncologyNational cancer center hospital east

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesMeredith pelsterValerie malyvanh jansenPrnewswire elevation oncology incElevation oncology incGroup limitedGastrointestinal research for sarah cannon instituteExchange commissionAmerican society of clinical oncologyCorporate communications investor relationsChief medical officerAssistant directorGastrointestinal researchSarah cannon research instituteAmerican societyClinical oncology

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesChunlei liValerie malyvanh jansenYakun wangElevation oncology incCorporate communications investor relationsAmerican society of clinical oncologyPrnewswire elevation oncology incExchange commissionGroup limitedDrug administrationAmerican societyClinical oncologyChief medical officerElevation oncologyChief scientific officer

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesValerie malyvanh jansenYakun wangCorporate communications investor relationsElevation oncology incGroup limitedDrug administrationAmerican society of clinical oncologyPrnewswire elevation oncology incExchange commissionAmerican societyClinical oncologyElevation oncologyChief medical officerPoster discussionMolecularly targeted agents